Navigation Links
Beta-Pro Expands Operations to Meet Demands for Human Cells in Hepatocyte Drug Discovery Market
Date:10/12/2010

CHARLOTTESVILLE, Va., Oct. 12 /PRNewswire/ -- Beta-Pro LLC, announced today that it has expanded its operations to accommodate increasing demands from pharmaceutical drug discovery and research institutes in the $2 billion hepatocyte market. The human cellular sciences company now manages extensive laboratory facilities in the University of Virginia Research Park in Charlottesville, Virginia.  

"Beta-Pro has already established a foothold in the human pancreatic islet cell market and has consistently been able to supply diabetes researchers and transplant centers with high-quality, clinical and transplantable human islets and other pancreatic biomaterials," said Beta-Pro Principle Scientific Advisor and Professor of Surgery at the University of Virginia, Kenneth L. Brayman, M.D., Ph.D.  "Based on our success we are now broadening the focus of our cellular services to include liver biology and the needs of pharmaceutical companies in testing drugs in human hepatocyte-cell cultures."

Beta-Pro partners with leading pharmaceutical companies and research organizations including: Pfizer, Eli Lilly, Genentech, Merck, Genomics Institute of the Novartis Research Foundation (GNF), and The Broad Institute in Cambridge, Massachusetts. Beta-Pro's new laboratory is designated as a good laboratory practice (GLP) facility and is now fully operational. The company has moved its snap-frozen cell bank to the new location and will use the facility to focus on hepatocytes and other human cell applications, including drug discovery services and toxicology screening using human cells.

About Beta-ProBeta-Pro isolates and distributes human pancreatic islet cells, acinar tissue, hepatocytes, adipose-derived stem cells, mesenchymal stem cells, and other biomaterials from surplus organs not placed for whole organ transplant in GMP and GLP facilities. The company also offers custom drug discovery and toxicology testing services using human cells for potential pharmacological applications. Beta-Pro charges and recovers fees for the costs for organ procurement, processing, preservation, quality control, storage, handling, and delivery of islets, other biomaterials, and biological data. For more information, call (434) 973-9456 or visit www.betaprolabs.com. Contact:

John Kelly PR(434) 296-5577john@johnkellypr.com
'/>"/>

SOURCE Beta-Pro LLC
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Beta-Pro Donates Human Islet Cells to Diabetes Researcher
2. MicuRx Pharmaceuticals Selects Next-Generation Antibiotic Candidate Targeting MRSA and Expands Operation in China
3. Hoya Vision Care Expands in Czech Republic
4. Oridion Expands its OEM Partnerships - New Agreement with Spacelabs Healthcare
5. InVitria Expands Sales Team
6. Enerkem Expands Executive Management Team
7. PSKW Expands Its Lawsuit Against McKesson to Seek Assignment of McKessons Patent Application
8. Supelco(R) Expands Ascentis(R) Express HPLC Columns Line for High-Speed and High-Efficiency Separations
9. BioElectronics Corp Aggressively Expands Sales into Middle East
10. Quintiles Expands Base for Growing Asia-Pacific Operations
11. CryoLife Expands Distribution of Hemostase MPH(R) to France through Laboratoire Gamida
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... PHILADELPHIA , June 27, 2016  Liquid ... today announced the funding of a Sponsored Research ... study circulating tumor cells (CTCs) from cancer patients.  ... changes in CTC levels correlate with clinical outcomes ... therapies. These data will then be employed to ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... While the ... such as the Cary 5000 and the 6000i models are higher end machines that ... the height of the spectrophotometer’s light beam from the bottom of the cuvette holder. ...
(Date:6/23/2016)... , June 23, 2016   Boston ... of novel compounds designed to target cancer stemness ... has been granted Orphan Drug Designation from the ... treatment of gastric cancer, including gastroesophageal junction (GEJ) ... inhibitor designed to inhibit cancer stemness pathways by ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. is pleased ... received AOAC Research Institute approval 061601. , “This is another AOAC-RI approval of ... Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods perform ...
Breaking Biology Technology:
(Date:5/16/2016)... YORK , May 16, 2016   EyeLock ... solutions, today announced the opening of an IoT Center ... to strengthen and expand the development of embedded iris ... an unprecedented level of convenience and security with unmatched ... authenticate one,s identity aside from DNA. EyeLock,s platform uses ...
(Date:5/9/2016)... UAE, May 9, 2016 Elevay ... comes to expanding freedom for high net worth professionals ... in today,s globally connected world, there is still no ... could ever duplicate sealing your deal with a firm ... passports by taking advantage of citizenship via investment programs ...
(Date:4/28/2016)... and BANGALORE, India , April 28, 2016 ... a product subsidiary of Infosys (NYSE: INFY ), ... a global partnership that will provide end customers ... mobile banking and payment services.      (Logo: ... innovation area for financial services, but it also plays a ...
Breaking Biology News(10 mins):